Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
becotatug vedotin + pucotenlimab + cisplatin
- Development stage
- Phase 3
- Lead developer
- Lepu Biopharma
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Becotatug vedotin + pucotenlimab + cisplatin is an investigational combination regimen being evaluated for the treatment of locally advanced, epidermal growth factor receptor (EGFR)-positive head and neck squamous cell carcinoma (HNSCC). The regimen combines three distinct therapeutic modalities: becotatug vedotin (an antibody-drug conjugate targeting EGFR conjugated to the microtubule inhibitor monomethyl auristatin E), pucotenlimab (a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1), and cisplatin (a platinum-based DNA-damaging chemotherapeutic agent). This triple combination leverages targeted cytotoxic delivery, immune checkpoint blockade, and DNA-damaging chemotherapy to maximize anti-tumor efficacy in the neoadjuvant setting prior to definitive surgery or chemoradiotherapy.
- Other names
- MRG003 + HX008 + cisplatinMRG003 + pucotenlimab + cisplatinbecotatug vedotin + HX008 + cisplatin
02
Targets
DNAEGFR (Epidermal growth factor receptor)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)PDCD1LG2 (Programmed cell death 1 ligand 2)
Beyond the preview
Go deeper on becotatug vedotin + pucotenlimab + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on becotatug vedotin + pucotenlimab + cisplatin.